Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M‐Positive Non‐Small‐Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial

LESSONS LEARNED. Non‐small‐cell lung cancer (NSCLC) represents 85% of lung cancer in elderly patients. In the present study performed in the 36 elderly subjects with epidermal growth factor receptor (EGFR) T790M mutation‐positive NSCLC, osimertinib 80 mg demonstrated statistically significant improv...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakao, Akira, Hiranuma, Osamu, Uchino, Junji, Sakaguchi, Chikara, Kita, Toshiyuki, Hiraoka, Noriya, Ishizuka, Tamotsu, Kubota, Yutaka, Kawasaki, Masayuki, Goto, Yasuhiro, Imai, Hisao, Hattori, Noboru, Nakatomi, Keita, Uramoto, Hidetaka, Uryu, Kiyoaki, Fukuda, Minoru, Uchida, Yasuki, Yokoyama, Toshihide, Akai, Masaya, Mio, Tadashi, Nagashima, Seiji, Chihara, Yusuke, Tamiya, Nobuyo, Kaneko, Yoshiko, Mouri, Takako, Yamada, Tadaaki, Yoshimura, Kenichi, Fujita, Masaki, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6516134/
https://www.ncbi.nlm.nih.gov/pubmed/30651400
http://dx.doi.org/10.1634/theoncologist.2019-0003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6516134/
https://www.ncbi.nlm.nih.gov/pubmed/30651400
http://dx.doi.org/10.1634/theoncologist.2019-0003

Ejemplares similares